Registration
 
All news
Top Stories
Editors' Picks
Stocks
Crypto
Economics
Currencies
Commodities
Business & Wealth
Market Voices
Eugene Komchuk
Eugene Komchuk

Vir Biotechnology advances Phase 3 ECLIPSE program for Hepatitis Delta treatment

Vir Biotechnology advances Phase 3 ECLIPSE program for Hepatitis Delta treatment
Vir advances Hepatitis Delta program

Vir Biotechnology announced ongoing progress in its Phase 3 ECLIPSE clinical program, pursuing a potential best-in-class treatment for Hepatitis Delta.

The company expressed encouragement about momentum within the Hepatitis Delta community to address significant unmet needs for patients affected by the liver disease.

Vir Biotechnology recently entered a multi-program partnership with Gilead Sciences to develop solid tumor therapies. The company also named David Liu as executive vice president and chief medical officer, bringing immuno-oncology and regulatory experience to its leadership team, according to a prior announcement on his appointment. These moves come as Vir advances late-stage programs in infectious diseases.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Editor's Picks for You

Between record and bubble: How Anthropic is approaching its IPO
  • By Mikhail Vnuchkov
  • 1 hour ago
Between record and bubble: How Anthropic is approaching its IPO
Editors' Picks
From Bitcoin to AI: How crypto companies are reinventing their businesses
  • By Olena Litvinenko
  • 23 hours ago
From Bitcoin to AI: How crypto companies are reinventing their businesses
Editors' Picks
Trezor security chief: It's easier to trick users than hack a crypto wallet
  • By Eugene Komchuk
  • Yesterday
Trezor security chief: It's easier to trick users than hack a crypto wallet
Editors' Picks
All Editors' Top Picks

Latest Vir Biotechnology News

Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
  • By Ksenia Gerey
  • 22.10.2026
Vir Biotechnology advances dual-masked TCE pipeline targeting difficult-to-treat solid tumors
Companies
#Vir Biotechnology
Vir Biotechnology to hold investor call on Q3 2026 performance
  • By Hanna Syniavska
  • 21.10.2026
Vir Biotechnology to hold investor call on Q3 2026 performance
Companies
#Vir Biotechnology
Gilead Sciences partners with Vir Biotechnology to advance multi-program solid tumor therapies
  • By Eugene Komchuk
  • 14.10.2026
Gilead Sciences partners with Vir Biotechnology to advance multi-program solid tumor therapies
Companies
#Vir Biotechnology
All Vir Biotechnology News
  • Mikhail Vnuchkov
  • 1 hour ago
Between record and bubble: How Anthropic is approaching its IPO
  • Olena Litvinenko
  • 23 hours ago
From Bitcoin to AI: How crypto companies are reinventing their businesses
  • Eugene Komchuk
  • Yesterday
Trezor security chief: It's easier to trick users than hack a crypto wallet
  • Dmytro Kharkov
  • Yesterday
How Ozempic and weight-loss drugs are quietly deflating beer volumes
  • Pavlo Kot
  • 25.10.2026
Q-Day for BTC: What happens if a quantum computer breaks Bitcoin?
  • Oksana Koneva
  • 34 min ago
Anas Alhajji: AI and oil concerns weigh on Asian currencies as Meta sees negative cash flow
  • Mykhailo Ihnatenko
  • 44 min ago
A 46-year support level comes into play for silver, Peter Spina notes
  • Yaroslav Dmytrenko
  • 49 min ago
Eurozone banks report tighter lending standards and lower credit flow, Daniel Kral notes
  • Pavlo Kot
  • 59 min ago
U.S. stocks rise pre-market amid large AI equity offerings, Gary Black notes
  • Oksana Koneva
  • 59 min ago
Mario Nawfal: Typical U.S., German, and British wealth fell since 2020 while Japan saw gains
Top News
  • Igor Krasulya
  • 14 min ago
Nvidia backs Meta AI ambitions with $3 billion investment
Nvidia backs Meta AI ambitions with $3 billion investment
  • Ivan Andriyenko
  • 1 hour ago
Gold struggles to hold $4,000 amid U.S. inflation concerns
Gold struggles to hold $4,000 amid U.S. inflation concerns
  • Andrey Mastykin
  • 2 hours ago
Anthropic reveals $81 billion loss ahead of planned IPO
Anthropic reveals $81 billion loss ahead of planned IPO
  • Olga Shendetskaya
  • 3 hours ago
U.S.-Canada trade talks gain momentum ahead of midterm elections
U.S.-Canada trade talks gain momentum ahead of midterm elections
  • Eugene Komchuk
  • 10 hours ago
Ripple receives approval to establish bank in the U.S.
Ripple receives approval to establish bank in the U.S.
Live News
  • Anton Kharitonov
  • Now
EUR/USD remains vulnerable near October lows ahead of central bank decisions
  • Eugene Komchuk
  • Now
Galaxy recommends accumulating Bitcoin ahead of the next rally
  • Hanna Syniavska
  • Now
Revolut launches UK personal loans as it expands beyond everyday banking
  • Anton Kharitonov
  • Now
EUR/USD remains under pressure as eurozone growth weakens ahead of ECB decision
  • Hanna Syniavska
  • Now
Turkey tightens investor rules after fund crisis affects at least 500,000 people
Who We Are
Business Solutions
For Users
TU News
Popular Sections
Disclosures
CONTACT US
Legal
We are in Social Media
© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186
  • Risk disclosure:

    Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

    That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.

  • Disclaimer:

    Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

    Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.

  • Disclosure of advertisers and revenues:

    All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

    Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.

onepercentfortheplanet.org https://gdpr.eu/ GDPR World Association of News Publishers